However, upon treatment of a subset of erlotinib conjugates with therapeutic light, EGFR-inhibitory activity is recovered that is effective in attenuating EGFR kinase activity and EGFR signal-dependent tumor cell proliferation. This evidence concerns the gene EGFR and neoplasm.